Drugs / RSV ΔNS2/Δ1313/I1314L
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03227029 | Sep 2017 → Dec 2019 | respiratory syncytial virus infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RSV/ΔNS2/Δ1313/I1314L | “This United States-based study compared 2 candidate vaccines: RSV/ΔNS2/Δ1313/I1314L, attenuated by NS2 gene-deletion and temperature-sensitivity mutation in the polymerase...” PMID 35732186 ↗ Dec 2022 |
| Modality | Vaccine | “This study evaluated the infectivity, safety, and immunogenicity of two recombinant live-attenuated RSV vaccines: RSV ΔNS2/Δ1313/I1314L and RSV 276.” NCT03227029 ↗ |
| Route | Intranasal | “10\^6 plaque-forming units (PFU); administered as nose drops” NCT03227029 ↗ |